DLL3-targeted PET/CT for detecting neuroendocrine carcinoma
Official title: Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma
Run by The First Affiliated Hospital of Xiamen University · NCT07458906 · Data updated 2026-11-12
We are testing a DLL3-targeted PET/CT scan to see if it better finds tumors in adults with suspected or confirmed neuroendocrine carcinoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Status | Recruiting |
| Started | March 10, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT07458906 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with suspected, newly diagnosed, or previously treated neuroendocrine carcinoma, with supportive imaging/pathology and elevated ProGRP or NSE (≥3× upper limit), able to consent and expected to live more than three months are ideal candidates.
✕Probably not a fit
Patients who cannot complete PET/CT, who have non-DLL3-expressing tumors, or who have very limited life expectancy or contraindications to PET/CT are unlikely to benefit from this imaging approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants undergo contemporaneous DLL3-targeted PET/CT and conventional imaging (CT, MRI, or 18F-FDG PET/CT) for initial staging or suspected recurrence. Tumor uptake on the DLL3 tracer will be quantified by SUVmax and lesion detection will be compared by visual reads against standard imaging. Tumor samples will be correlated by immunohistochemistry to determine whether tracer uptake reflects DLL3 expression, and intertumoral heterogeneity will be assessed using the coefficient of variation of SUVmax across lesions. The diagnostic accuracy of DLL3-targeted PET/CT will be calculated and compared to conventional imaging.
Why it matters
Potential benefit: If successful, DLL3-targeted PET/CT could more accurately locate DLL3-expressing neuroendocrine cancer lesions and help guide treatment decisions.
How similar studies have gone: DLL3-targeted imaging is a relatively new approach with limited published clinical data, although DLL3 has been explored as a therapeutic and diagnostic target in related neuroendocrine and small cell cancers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report); * Serum ProGRP or NSE level ≥ 3 times the upper limit of normal; * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. * Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits; Exclusion Criteria: * The inability or unwillingness of the research participant or legal representative to provide written informed consent. * Inability to complete PET/CT imaging.
Where it's running
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China Recruiting
Study contacts
- Study coordinator: Liang Zhao
- Email: wzhaoliang01@163.com
- Phone: 86 18818350620
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors
A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.
-
68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery
This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.
-
Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers
Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.
-
TLN-499 plus venetoclax in relapsed or refractory solid tumors
Doctors are testing whether TLN-499 added to venetoclax can help patients with relapsed or refractory solid tumors, including SCLC and certain neuroendocrine cancers.
-
Making PET-like images from CT to improve lung cancer diagnosis and care
This project will test whether PET-like images generated from routine diagnostic CT scans can help doctors diagnose, stage, and plan treatment for people with non-small cell lung cancer who are having PET-CT and pathology tests.
-
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This study uses PET/CT imaging with two tracers to see if they can better stage NPC and predict early response to neoadjuvant immunotherapy in adults with newly diagnosed NPC.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.